Halozyme Therapeutics, Inc.

NasdaqGS:HALO 주식 보고서

시가총액: US$5.7b

Halozyme Therapeutics 관리

관리 기준 확인 2/4

Halozyme Therapeutics CEO는 Helen Torley, Jan2014 에 임명되었습니다 의 임기는 10.83 년입니다. 총 연간 보상은 $ 11.82M, 7.8% 로 구성됩니다. 7.8% 급여 및 92.2% 보너스(회사 주식 및 옵션 포함). 는 $ 30.32M 가치에 해당하는 회사 주식의 0.53% 직접 소유합니다. 30.32M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 10.8 년입니다.

주요 정보

Helen Torley

최고 경영자

US$11.8m

총 보상

CEO 급여 비율7.8%
CEO 임기10.8yrs
CEO 소유권0.5%
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간10.8yrs

최근 관리 업데이트

Recent updates

Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal

Nov 20

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 05

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Oct 29
Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Halozyme Therapeutics: Behind The Pullback

Oct 22

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Aug 13
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Jul 17
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Halozyme Therapeutics: The Story Brightens

Jun 07

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Apr 26
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Apr 10

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Apr 05
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Mar 15
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09
We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28
Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

CEO 보상 분석

Helen Torley 의 보수는 Halozyme Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

US$392m

Jun 30 2024n/an/a

US$337m

Mar 31 2024n/an/a

US$319m

Dec 31 2023US$12mUS$920k

US$282m

Sep 30 2023n/an/a

US$254m

Jun 30 2023n/an/a

US$234m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$10mUS$872k

US$202m

Sep 30 2022n/an/a

US$211m

Jun 30 2022n/an/a

US$366m

Mar 31 2022n/an/a

US$435m

Dec 31 2021US$7mUS$830k

US$403m

Sep 30 2021n/an/a

US$409m

Jun 30 2021n/an/a

US$229m

Mar 31 2021n/an/a

US$163m

Dec 31 2020US$7mUS$791k

US$129m

Sep 30 2020n/an/a

US$22m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$80m

Dec 31 2019US$6mUS$761k

-US$72m

Sep 30 2019n/an/a

-US$40m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$51m

Dec 31 2018US$6mUS$725k

-US$80m

Sep 30 2018n/an/a

US$46m

Jun 30 2018n/an/a

US$76m

Mar 31 2018n/an/a

US$68m

Dec 31 2017US$5mUS$671k

US$63m

보상 대 시장: Helen 의 총 보상 ($USD 11.82M )은 US 시장( $USD 7.94M ).

보상과 수익: Helen 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Helen Torley (61 yo)

10.8yrs

테뉴어

US$11,820,858

보상

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...

리더십 팀

이름위치테뉴어보상소유권
Helen Torley
President10.8yrsUS$11.82m0.53%
$ 30.3m
Nicole LaBrosse
Senior VP & CFO2.8yrsUS$3.85m0.012%
$ 693.8k
Michael LaBarre
Senior VP & CTOno dataUS$3.24m0.14%
$ 7.8m
Mark Snyder
Senior VP & Chief Legal Officer2.8yrsUS$3.61m0.0092%
$ 523.4k
Cortney Caudill
Chief Operations Officer1.1yrs데이터 없음데이터 없음
Tram Bui
Head of Investor Relations & Corporate Communications2.8yrs데이터 없음데이터 없음
Amy Fox
Chief Human Resources Officer4.8yrs데이터 없음데이터 없음
Gary Grote
Chief Commercial Officer1.5yrs데이터 없음데이터 없음
Christopher Wahl
Chief Business Officer1.3yrs데이터 없음데이터 없음
Charles Theuer
Chief Medical Officerless than a year데이터 없음데이터 없음

2.8yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: HALO 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Helen Torley
President10.8yrsUS$11.82m0.53%
$ 30.3m
Connie Matsui
Independent Director18.3yrsUS$460.02k0.15%
$ 8.4m
Jeffrey Henderson
Independent Chair of the Board9.3yrsUS$555.02k0.037%
$ 2.1m
Daniel Von Hoff
Member of the Scientific Advisory Board20.3yrs데이터 없음데이터 없음
Barbara Duncan
Independent Director1.8yrsUS$528.15k데이터 없음
Jeffrey Bleil
Member of the Advisory Boardno data데이터 없음데이터 없음
Gregory Frost
Chairman of Scientific Advisory Board10.8yrsUS$68.17k데이터 없음
Gerhard Baumgartner
Member of Scientific Advisory Board20.4yrs데이터 없음데이터 없음
Sue Bailey
Member of Scientific Advisory Board19.3yrs데이터 없음데이터 없음
Matthew Posard
Independent Director11.7yrsUS$471.83k0.039%
$ 2.2m
Akiko Miyashita
Independent Director2.7yrsUS$455.02k0.011%
$ 639.7k
Bernadette Connaughton
Independent Director6.2yrsUS$470.02k0.032%
$ 1.8m

10.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: HALO 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).